XKR6
geneOn this page
Summary
XKR6 (XK related 6, HGNC:27806) is a protein-coding gene on chromosome 8p23.1, encoding XK-related protein 6 (Q5GH73).
Predicted to be involved in apoptotic process involved in development; engulfment of apoptotic cell; and phosphatidylserine exposure on apoptotic cell surface. Predicted to be located in membrane. Predicted to be active in plasma membrane.
Source: NCBI Gene 286046 — RefSeq curated summary.
At a glance
- GWAS associations: 133
- Clinical variants (ClinVar): 69 total
- MANE Select transcript:
NM_173683
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:27806 |
| Approved symbol | XKR6 |
| Name | XK related 6 |
| Location | 8p23.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Ensembl gene | ENSG00000171044 |
| Ensembl biotype | protein_coding |
| Entrez | 286046 |
Gene structure
Transcript identifiers
Ensembl transcripts: 4 — 3 protein_coding, 1 nonsense_mediated_decay
ENST00000297303, ENST00000382461, ENST00000416569, ENST00000529336
RefSeq mRNA: 1 — MANE Select: NM_173683
NM_173683
CCDS: CCDS5978
Canonical transcript exons
ENST00000416569 — 3 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001670462 | 10896045 | 10898916 |
| ENSE00002170546 | 11200576 | 11201833 |
| ENSE00004013922 | 10924634 | 10924830 |
Expression profiles
Bgee: expression breadth ubiquitous, 167 present calls, max score 93.57.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 3.3006 / max 73.4476, expressed in 1052 samples.
FANTOM5 promoters (4 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 91824 | 1.8789 | 752 |
| 91823 | 1.0410 | 554 |
| 91825 | 0.1928 | 78 |
| 91822 | 0.1879 | 84 |
Top tissues by expression
244 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| buccal mucosa cell | CL:0002336 | 93.57 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 86.55 | gold quality |
| middle temporal gyrus | UBERON:0002771 | 83.86 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 82.22 | gold quality |
| Brodmann (1909) area 23 | UBERON:0013554 | 80.95 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 78.31 | gold quality |
| right testis | UBERON:0004534 | 78.14 | gold quality |
| left testis | UBERON:0004533 | 77.76 | gold quality |
| body of pancreas | UBERON:0001150 | 77.23 | gold quality |
| primary visual cortex | UBERON:0002436 | 76.81 | gold quality |
| granulocyte | CL:0000094 | 76.57 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 76.03 | gold quality |
| ventricular zone | UBERON:0003053 | 75.91 | gold quality |
| pancreas | UBERON:0001264 | 75.90 | gold quality |
| islet of Langerhans | UBERON:0000006 | 75.42 | gold quality |
| testis | UBERON:0000473 | 75.27 | gold quality |
| stromal cell of endometrium | CL:0002255 | 73.88 | gold quality |
| spleen | UBERON:0002106 | 73.59 | gold quality |
| esophagus mucosa | UBERON:0002469 | 73.13 | gold quality |
| lymph node | UBERON:0000029 | 73.04 | gold quality |
| bone marrow cell | CL:0002092 | 73.02 | gold quality |
| adrenal tissue | UBERON:0018303 | 72.74 | gold quality |
| occipital lobe | UBERON:0002021 | 72.50 | gold quality |
| right lung | UBERON:0002167 | 72.36 | gold quality |
| small intestine Peyer’s patch | UBERON:0003454 | 72.00 | gold quality |
| minor salivary gland | UBERON:0001830 | 71.90 | gold quality |
| body of stomach | UBERON:0001161 | 71.86 | gold quality |
| left adrenal gland | UBERON:0001234 | 71.74 | gold quality |
| skin of abdomen | UBERON:0001416 | 71.69 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 71.10 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | no | 2.36 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
164 targeting XKR6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-5011-5P | 100.00 | 83.46 | 5820 |
| HSA-MIR-190A-3P | 100.00 | 80.35 | 5520 |
| HSA-MIR-8485 | 100.00 | 77.57 | 4731 |
| HSA-MIR-29A-3P | 100.00 | 73.11 | 1835 |
| HSA-MIR-29B-3P | 100.00 | 73.18 | 1833 |
| HSA-MIR-29C-3P | 100.00 | 73.15 | 1833 |
| HSA-MIR-4682 | 100.00 | 68.89 | 1258 |
| HSA-MIR-200B-3P | 100.00 | 73.31 | 2693 |
| HSA-MIR-200C-3P | 100.00 | 73.35 | 2685 |
| HSA-MIR-429 | 100.00 | 73.44 | 2698 |
| HSA-MIR-3924 | 100.00 | 72.09 | 2394 |
| HSA-MIR-3646 | 100.00 | 73.56 | 5283 |
| HSA-MIR-511-3P | 99.99 | 68.85 | 1467 |
| HSA-MIR-3662 | 99.99 | 73.82 | 5684 |
| HSA-MIR-6870-5P | 99.99 | 68.55 | 2115 |
| HSA-MIR-8068 | 99.98 | 73.85 | 2376 |
| HSA-MIR-5696 | 99.98 | 72.36 | 4487 |
| HSA-MIR-4775 | 99.98 | 75.00 | 6394 |
| HSA-MIR-3617-3P | 99.98 | 67.86 | 918 |
| HSA-MIR-568 | 99.98 | 69.86 | 2084 |
| HSA-MIR-4723-5P | 99.97 | 68.70 | 2034 |
| HSA-MIR-5698 | 99.97 | 68.49 | 2029 |
| HSA-MIR-7111-5P | 99.97 | 68.48 | 2062 |
| HSA-MIR-3910 | 99.95 | 71.13 | 2227 |
| HSA-MIR-9983-3P | 99.94 | 71.48 | 3631 |
| HSA-MIR-101-3P | 99.94 | 75.03 | 2230 |
| HSA-MIR-6835-3P | 99.93 | 70.49 | 2904 |
| HSA-MIR-539-5P | 99.93 | 70.30 | 2855 |
| HSA-MIR-515-5P | 99.92 | 69.82 | 2343 |
| HSA-MIR-519E-5P | 99.92 | 69.62 | 2358 |
Literature-anchored findings (GeneRIF, showing 3)
- XKR6 single nucleotide polymorphism rs7460469 is associated with childhood-onset systemic lupus erythematosus. (PMID:29967481)
- XKR6 rs7819412 A allele was related to increased serum triglyceride levels in coronary artery disease, total cholesterol levels in ischemic stroke patients and high risk of CAD and ischemic stroke. (PMID:31429711)
- XKR6 rs7014968 SNP Increases Serum Total Cholesterol Levels and the Risk of Coronary Heart Disease and Ischemic Stroke. (PMID:32024373)
Cross-species orthologs
4 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | xkr6a | ENSDARG00000020443 |
| danio_rerio | xkr6b | ENSDARG00000043410 |
| mus_musculus | Xkr6 | ENSMUSG00000035067 |
| rattus_norvegicus | Xkr6 | ENSRNOG00000011634 |
Paralogs (5): XKR8 (ENSG00000158156), XKR4 (ENSG00000206579), XKR9 (ENSG00000221947), XKR7 (ENSG00000260903), XKR5 (ENSG00000275591)
Protein
Protein identifiers
XK-related protein 6 — Q5GH73 (reviewed: Q5GH73)
All UniProt accessions (4): Q5GH73, H0YEU9, H7BYF9, Q96KT3
UniProt curated annotations — full annotation on UniProt →
Subcellular location. Cell membrane.
Similarity. Belongs to the XK family.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q5GH73-1 | 1 | yes |
| Q5GH73-2 | 2 |
RefSeq proteins (1): NP_775954* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR018629 | XK-rel | Family |
| IPR050895 | XK-related_scramblase | Family |
Pfam: PF09815
UniProt features (13 total): transmembrane region 7, compositionally biased region 2, region of interest 2, chain 1, splice variant 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q5GH73-F1 | 64.85 | 0.26 |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 127 (showing top):
TGGTGCT_MIR29A_MIR29B_MIR29C, GOBP_PLASMA_MEMBRANE_ORGANIZATION, GOBP_APOPTOTIC_CELL_CLEARANCE, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_REGULATION_OF_MEMBRANE_LIPID_DISTRIBUTION, GOBP_ORGANOPHOSPHATE_ESTER_TRANSPORT, CATTTCA_MIR203, GOBP_ENDOMEMBRANE_SYSTEM_ORGANIZATION, GOBP_APOPTOTIC_PROCESS_INVOLVED_IN_DEVELOPMENT, GOBP_PHOSPHOLIPID_TRANSPORT, GOBP_MEMBRANE_ORGANIZATION, GOBP_MEMBRANE_INVAGINATION, GOBP_IMPORT_INTO_CELL, GOBP_LIPID_LOCALIZATION, TGCCTTA_MIR124A
GO Biological Process (3): engulfment of apoptotic cell (GO:0043652), phosphatidylserine exposure on apoptotic cell surface (GO:0070782), apoptotic process involved in development (GO:1902742)
GO Molecular Function (0):
GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| phagocytosis, engulfment | 1 |
| apoptotic cell clearance | 1 |
| plasma membrane phospholipid scrambling | 1 |
| phospholipid scramblase activity | 1 |
| execution phase of apoptosis | 1 |
| apoptotic process | 1 |
| anatomical structure development | 1 |
| membrane | 1 |
| cell periphery | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
620 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| XKR6 | FAM167A | Q96KS9 | 743 |
| XKR6 | MTMR9 | Q96QG7 | 649 |
| XKR6 | BLK | P51451 | 626 |
| XKR6 | SLC35G5 | Q96KT7 | 572 |
| XKR6 | LCA5L | O95447 | 539 |
| XKR6 | CCM2 | Q9BSQ5 | 528 |
| XKR6 | KEL | P23276 | 505 |
| XKR6 | PPP1R3B | Q86XI6 | 498 |
| XKR6 | TNKS | O95271 | 495 |
| XKR6 | MSRA | Q9UJ68 | 479 |
| XKR6 | TMEM63B | Q5T3F8 | 478 |
| XKR6 | CTSB | P07858 | 477 |
| XKR6 | PXK | Q7Z7A4 | 470 |
| XKR6 | MFHAS1 | Q9Y4C4 | 446 |
| XKR6 | SH3BGR | P55822 | 432 |
IntAct
3 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| XKR6 | VIM | psi-mi:“MI:0915”(physical association) | 0.400 |
| XKR6 | SLC27A3 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (8): XKR6 (Proximity Label-MS), UBAC2 (Affinity Capture-MS), SLC27A3 (Affinity Capture-MS), THEM6 (Affinity Capture-MS), RETSAT (Affinity Capture-MS), XKR6 (Cross-Linking-MS (XL-MS)), XKR6 (Affinity Capture-RNA), XKR6 (Affinity Capture-RNA)
ESM2 similar proteins: A0JPH4, A2AWP8, A2RRU4, A2SXS5, A4D2P6, A6QM06, D4A6L0, E1BBQ2, E9Q6C8, F1LQY6, O00255, O88559, O94827, P29590, P56726, P97260, P97698, Q0GA42, Q0P5I0, Q0VF94, Q12770, Q17RQ9, Q29RM4, Q49LS8, Q5GH57, Q5GH73, Q5MNU5, Q5SNT2, Q5T848, Q69Z89, Q6DVA0, Q6GQT6, Q6IEE7, Q70EL4, Q8BUM9, Q8C190, Q8C419, Q8NC56, Q8TCT7, Q91ZP9
Diamond homologs: E9Q6C8, Q49LS1, Q49LS4, Q49LS6, Q49LS7, Q49LS8, Q49LS9, Q4VV71, Q5GH56, Q5GH57, Q5GH59, Q5GH64, Q5GH67, Q5GH72, Q5GH73, Q5GH76, Q49LS3, Q5GH62, Q5GH66, Q6UX68, Q8C0T0, Q9H6D3, A8Y2U2, O17386, Q49LR9, Q49LS0, Q5GH70, Q9QXY7
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
69 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 64 |
| Likely benign | 3 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
4033 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 8:10924632:A:AC | donor_gain | 1.0000 |
| 8:10924633:C:CC | donor_gain | 1.0000 |
| 8:10924633:CAGGG:C | donor_gain | 1.0000 |
| 8:10924626:GCACT:G | donor_loss | 0.9900 |
| 8:10924627:CACT:C | donor_loss | 0.9900 |
| 8:10924628:ACTC:A | donor_loss | 0.9900 |
| 8:10924629:CTCA:C | donor_loss | 0.9900 |
| 8:10924630:T:TA | donor_loss | 0.9900 |
| 8:10924631:C:CC | donor_loss | 0.9900 |
| 8:10924632:ACAGG:A | donor_loss | 0.9900 |
| 8:10924633:C:CT | donor_loss | 0.9900 |
| 8:10924826:TATAC:T | acceptor_gain | 0.9900 |
| 8:10924827:ATAC:A | acceptor_gain | 0.9900 |
| 8:10924828:TAC:T | acceptor_gain | 0.9900 |
| 8:10924831:C:CA | acceptor_loss | 0.9900 |
| 8:10924836:C:CT | acceptor_gain | 0.9900 |
| 8:10924836:C:T | acceptor_gain | 0.9900 |
| 8:10924843:A:AC | acceptor_gain | 0.9900 |
| 8:10924843:A:C | acceptor_gain | 0.9900 |
| 8:11001950:T:TA | donor_gain | 0.9900 |
| 8:11027729:T:C | acceptor_gain | 0.9900 |
| 8:11104453:G:C | donor_gain | 0.9900 |
| 8:11137539:CCCA:C | donor_gain | 0.9900 |
| 8:11200573:TA:T | donor_loss | 0.9900 |
| 8:10924625:GGCAC:G | donor_loss | 0.9800 |
| 8:10924633:CA:C | donor_gain | 0.9800 |
| 8:10924633:CAGG:C | donor_gain | 0.9800 |
| 8:10924829:AC:A | acceptor_gain | 0.9800 |
| 8:10924830:CC:C | acceptor_gain | 0.9800 |
| 8:10924831:C:CC | acceptor_gain | 0.9800 |
AlphaMissense
4139 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 8:10898067:C:A | R604M | 1.000 |
| 8:10898087:C:A | W597C | 1.000 |
| 8:10898087:C:G | W597C | 1.000 |
| 8:10898089:A:G | W597R | 1.000 |
| 8:10898089:A:T | W597R | 1.000 |
| 8:10898124:A:G | I585T | 1.000 |
| 8:10898124:A:T | I585N | 1.000 |
| 8:11200576:C:A | R255M | 1.000 |
| 8:11200793:A:G | W183R | 1.000 |
| 8:11200793:A:T | W183R | 1.000 |
| 8:10898040:A:G | L613P | 0.999 |
| 8:10898057:T:A | R607S | 0.999 |
| 8:10898057:T:G | R607S | 0.999 |
| 8:10898058:C:A | R607I | 0.999 |
| 8:10898058:C:G | R607T | 0.999 |
| 8:10898061:A:G | L606P | 0.999 |
| 8:10898066:C:A | R604S | 0.999 |
| 8:10898066:C:G | R604S | 0.999 |
| 8:10898067:C:G | R604T | 0.999 |
| 8:10898070:T:A | D603V | 0.999 |
| 8:10898070:T:G | D603A | 0.999 |
| 8:10898071:C:G | D603H | 0.999 |
| 8:10898118:A:C | I587S | 0.999 |
| 8:10898124:A:C | I585S | 0.999 |
| 8:10898189:G:C | F563L | 0.999 |
| 8:10898189:G:T | F563L | 0.999 |
| 8:10898190:A:G | F563S | 0.999 |
| 8:10898191:A:G | F563L | 0.999 |
| 8:10898610:C:T | G423E | 0.999 |
| 8:10898611:C:A | G423W | 0.999 |
dbSNP variants (sampled 300 via entrez): RS1000005280 (8:11021239 G>A), RS1000009708 (8:10964509 T>C), RS1000019071 (8:11108952 C>A,G,T), RS1000020513 (8:10975197 A>G), RS1000024177 (8:11112665 G>A), RS1000032789 (8:11141714 T>C), RS1000034989 (8:10917673 G>A), RS1000042008 (8:11139812 G>A), RS1000045759 (8:11036250 G>C), RS1000050972 (8:11091496 A>C), RS1000051855 (8:11116600 A>C,G), RS1000052895 (8:10905908 C>T), RS1000054024 (8:11193031 T>C), RS1000057864 (8:10945038 G>A), RS1000067437 (8:11053568 T>G)
Disease associations
OMIM: gene `` | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
133 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST000286_1 | Triglycerides | 3.000000e-08 |
| GCST000758_12 | Triglycerides | 1.000000e-08 |
| GCST000847_5 | Retinal vascular caliber | 4.000000e-07 |
| GCST002322_14 | Asthma and hay fever | 4.000000e-07 |
| GCST002527_6 | Eosinophilic esophagitis | 5.000000e-08 |
| GCST002928_12 | Nickel levels | 1.000000e-06 |
| GCST003103_2 | Systemic lupus erythematosus | 8.000000e-06 |
| GCST003998_11 | Joint mobility (Beighton score) | 3.000000e-09 |
| GCST004017_1 | Neuroticism | 3.000000e-24 |
| GCST004351_19 | Bone ultrasound measurement (broadband ultrasound attenuation) | 4.000000e-07 |
| GCST005576_17 | Intracranial aneurysm | 7.000000e-07 |
| GCST005752_49 | Systemic lupus erythematosus | 1.000000e-07 |
| GCST005835_3 | Remission after SSRI treatment in MDD or neuroticism | 1.000000e-12 |
| GCST006170_19 | Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test) | 1.000000e-12 |
| GCST006172_13 | Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test) | 3.000000e-09 |
| GCST006172_39 | Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test) | 2.000000e-08 |
| GCST006434_89 | Systolic blood pressure x alcohol consumption interaction (2df test) | 1.000000e-20 |
| GCST007293_1 | Body fat distribution (arm fat ratio) | 3.000000e-16 |
| GCST007293_108 | Body fat distribution (arm fat ratio) | 8.000000e-14 |
| GCST007293_71 | Body fat distribution (arm fat ratio) | 5.000000e-07 |
| GCST007294_182 | Body fat distribution (trunk fat ratio) | 1.000000e-07 |
| GCST007325_130 | General risk tolerance (MTAG) | 6.000000e-11 |
| GCST007325_168 | General risk tolerance (MTAG) | 1.000000e-08 |
| GCST007325_197 | General risk tolerance (MTAG) | 2.000000e-08 |
| GCST007325_55 | General risk tolerance (MTAG) | 3.000000e-29 |
| GCST007327_49 | Smoking status (ever vs never smokers) | 1.000000e-08 |
| GCST007329_16 | Automobile speeding propensity | 9.000000e-09 |
| GCST007709_180 | General factor of neuroticism | 2.000000e-09 |
| GCST007709_184 | General factor of neuroticism | 4.000000e-11 |
| GCST007709_186 | General factor of neuroticism | 5.000000e-11 |
EFO canonical traits (22, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004530 | triglyceride measurement |
| EFO:0004731 | eye measurement |
| EFO:0007905 | joint hypermobility measurement |
| EFO:0007660 | neuroticism measurement |
| EFO:0004514 | bone quantitative ultrasound measurement |
| EFO:0005658 | response to selective serotonin reuptake inhibitor |
| EFO:0006335 | systolic blood pressure |
| EFO:0006340 | mean arterial pressure |
| EFO:0004329 | alcohol drinking |
| EFO:0004341 | body fat distribution |
| EFO:0008579 | risk-taking behaviour |
| EFO:0004318 | smoking behavior |
| EFO:0005670 | smoking initiation |
| EFO:0008111 | diet measurement |
| EFO:0007863 | illness severity status |
| EFO:0004346 | neuroimaging measurement |
| EFO:0009819 | comparative body size at age 10, self-reported |
| EFO:0005665 | white matter hyperintensity measurement |
| EFO:0007789 | BMI-adjusted waist circumference |
| EFO:0007788 | BMI-adjusted waist-hip ratio |
| EFO:0009863 | anxiety measurement |
| EFO:0008039 | BMI-adjusted hip circumference |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
20 total (human), top 20 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| bisphenol A | affects methylation, affects cotreatment, increases methylation | 2 |
| Benzo(a)pyrene | affects methylation, increases expression | 2 |
| Valproic Acid | affects expression, decreases expression | 2 |
| Aflatoxin B1 | increases methylation | 2 |
| Cadmium Chloride | decreases expression, increases abundance, increases expression | 2 |
| methylmercuric chloride | decreases expression | 1 |
| sodium arsenite | decreases expression | 1 |
| belinostat | increases expression | 1 |
| abrine | increases expression | 1 |
| bisphenol S | decreases methylation | 1 |
| Sunitinib | decreases expression | 1 |
| Fulvestrant | affects cotreatment, increases methylation | 1 |
| Cadmium | decreases expression, increases abundance | 1 |
| Estradiol | decreases expression, affects cotreatment | 1 |
| Ethyl Methanesulfonate | increases expression | 1 |
| Folic Acid | decreases expression | 1 |
| Formaldehyde | increases expression | 1 |
| Methyl Methanesulfonate | increases expression | 1 |
| Smoke | decreases expression | 1 |
| Antirheumatic Agents | increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
- Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): brain aneurysm, eosinophilic esophagitis, hand, foot and mouth disease, myopathy, seasonal allergic rhinitis